Here's what should alarm you about women's health right now: the conditions that are hardest to diagnose are also the easiest to ignore. And the companies with the most to gain aren't exactly rushing to change that.
Take adenomyosis. Most people have never heard of it. Fewer still understand that it affects millions of women, causes severe pain, and remains notoriously difficult to diagnose. Yet while awareness campaigns light up social media, the diagnostic infrastructure hasn't budged in years. Why? Because there's no quick fix, no blockbuster drug, no easy revenue stream.
Compare that to the explosion of consumer wellness products aimed at women. Compression leggings. Brain health supplements. Travel wear engineered for female bodies. These products are everywhere, heavily marketed, and their manufacturers rake in considerable profits. They're also solving problems that women already know how to identify in themselves. A sore leg? Buy leggings. Worried about brain fog? Buy the supplement.
But a woman experiencing debilitating pelvic pain for years without a diagnosis? The market has largely left her behind.
This isn't coincidental. It's a direct reflection of where incentives flow in the wellness industry. Companies invest in products where consumer demand is already conscious and purchasing power is activated. They don't necessarily invest in solving the hard medical problems that would require years of research, regulatory navigation, and a smaller addressable market.
The result is a distorted picture of women's health that prioritizes what's profitable over what's pressing.
Women's health advocacy has made real strides in recent years. More voices are speaking up about hormonal conditions, reproductive health, and the ways women's symptoms get dismissed. But visibility alone doesn't equal action from the institutions that could actually move the needle. A woman knowing that adenomyosis is "invisible" doesn't help her get diagnosed faster if the diagnostic tools haven't evolved.
Meanwhile, the wellness industry captures attention and capital by selling women optimized versions of problems they already understand. This isn't inherently harmful. But it crowds out the harder conversations about systemic gaps in medical research, diagnostic accuracy, and treatment options for conditions that don't fit neatly into a consumer product.
Here's the other problem: these markets reinforce a troubling narrative. They suggest that women's health is primarily a self-optimization project. Buy the right product, improve your own wellness, take control of your own body. This message feels empowering. And it can be. But it also lets healthcare systems, researchers, and yes, companies, off the hook for actually solving entrenched problems.
A woman buying compression leggings isn't the issue. The issue is that we've created a wellness ecosystem where that transaction is celebrated as innovation while a 35-year-old woman still waits years for someone to properly diagnose her adenomyosis.
The question readers should ask isn't whether these products work. It's whether the industry's incentive structure is actually aligned with women's health, or just with women's spending.
Until we see real investment in diagnosis, treatment development, and research for the conditions that remain medically mysterious, we should remain skeptical of the narrative that women's health is being "solved" by wellness entrepreneurs. Some of it is. Some of it absolutely isn't.
And the companies banking on the former would prefer you don't notice the latter.